A5020144229- Alzheimer's disease research and treatments
- Oral microbiology and periodontitis research
- Cancer Research and Treatments
- Telomeres, Telomerase, and Senescence
- Dementia and Cognitive Impairment Research
- Genetics, Aging, and Longevity in Model Organisms
- Cancer Treatment and Pharmacology
- RNA Interference and Gene Delivery
- S100 Proteins and Annexins
- Immune Response and Inflammation
- Cancer Immunotherapy and Biomarkers
- Chemotherapy-induced cardiotoxicity and mitigation
- Salivary Gland Disorders and Functions
- Cholinesterase and Neurodegenerative Diseases
- Immunotherapy and Immune Responses
- Neurobiology of Language and Bilingualism
- Angiogenesis and VEGF in Cancer
- Advanced biosensing and bioanalysis techniques
- Diabetes and associated disorders
- Tissue Engineering and Regenerative Medicine
- Tryptophan and brain disorders
- Neuroinflammation and Neurodegeneration Mechanisms
- NF-κB Signaling Pathways
Polaroid (United States)
2017-2025
Doxorubicin is a highly effective anticancer agent, but its clinical use restricted by severe side effects, including atherosclerosis and cardiomyopathy. These complications are partly attributed to doxorubicin's ability induce endothelial-to-mesenchymal transition (EndMT) in vascular endothelial cells, critical process the initiation progression of GV1001, multifunctional peptide with anti-inflammatory, anti-cancer, antioxidant, anti-Alzheimer's properties, has demonstrated inhibition...
Abstract Background Our previous studies showed that GV1001 has various protective effects against β-amyloid and other stressors. Based on these findings, we hypothesized might have beneficial in patients with Alzheimer’s disease (AD). Methods A phase 2, double-blind, parallel-group, placebo-controlled, 6-month randomized clinical trial was performed to evaluate the safety efficacy of subcutaneously administered GV1001. Between September 2017 2019, 13 centers South Korea recruited...
GV1001, a 16 amino acid peptide derived from the catalytic segment of human telomerase reverse transcriptase, was developed as an anti-cancer vaccine. Subsequently, it found to exhibit anti-inflammatory and anti-Alzheimer’s disease properties. Periodontitis is risk factor for variety systemic diseases, including atherosclerosis, process in which chronic vascular inflammation results formation plaques containing lipids, macrophages, foam cells, tissue debris on intima. Thus, we investigated...
GV1001 protects neural cells from amyloid-β (Aβ) toxicity and other stressors in vitro studies demonstrates clinically beneficial effects patients with moderate to severe Alzheimer's disease (AD). Here, we investigated the protective mechanism of action triple transgenic AD (3xTg-AD) mice. We found that improved memory cognition middle- old-aged 3xTg-AD Additionally, it reduced Aβ oligomer phospho-tau (Ser202 Thr205) levels brain, mitigated neuroinflammation by promoting a neuroprotective...
GV1001, which mimics the activity of human telomerase reverse transcriptase, protects neural cells from amyloid beta (Aβ) toxicity and other stressors through extra-telomeric function, as noted in our prior vitro studies. As per a recent phase II clinical trial, it improves cognitive function patients with moderate to severe dementia. However, underlying protective mechanisms remain unclear. This study aimed investigate effects GV1001 on neurodegeneration, senescence, survival triple...
GV1001, an anticancer vaccine, exhibits other biological functions, including anti-inflammatory and antioxidant activity. It also suppresses the development of ligature-induced periodontitis in mice. Porphyromonas gingivalis (Pg), a major human oral bacterium implicated periodontitis, is associated with various systemic disorders, such as atherosclerosis Alzheimer's disease (AD). This study aimed to explore protective effects GV1001 against Pg-induced periodontal disease, atherosclerosis,...
GV1001 is a 16‑amino acid peptide derived from the human telomerase reverse transcriptase (hTERT) protein (616‑626; EARPALLTSRLRFIPK), which lies within domain. Originally developed as an anticancer vaccine, demonstrates diverse cellular effects, including anti‑inflammatory, tumor suppressive and antiviral effects. In present study, radioprotective antifibrotic effects of were demonstrated through suppressing transforming growth factor‑β (TGF‑β) signaling. Proliferating keratinocytes...
The efficacy and safety of GV1001 have been demonstrated in patients with moderate-to-severe Alzheimer's disease (AD). In this study, we aimed to further demonstrate the effectiveness using subscales Severe Impairment Battery (SIB), which is a validated measure assess cognitive function AD.
Telomerase activation, a critical step in cancer progression, occurs approximately 95% of breast cases. is an attractive therapeutic target for owing to its unique expression pattern. GV1001, telomerase-derived peptide, loaded onto human leukocyte antigen (HLA) class II antigen-presenting cells and binds CD4+ T cell activating immune responses. This study aimed evaluate the effectiveness safety co-administration GV1001 cytotoxic chemotherapy patients with heavily-treated metastatic cancer.We...